Robert Bradway vs Howard Robin

Robert Bradway

CEO of Amgen

BIO: Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012. Mr. Bradway is responsible for the Amgen's global commercial operations, manufacturing operations, information technology, global government affairs and worldwide compliance and business ethics organizations. He served as the President of Amgen Inc. from May 2010 to May 2012. He served as the Chief Operating Officer of Amgen from May 2010 to May 23, 2012. He served as the Chief Financial Officer and Executive Vice President at Amgen Inc. from April 10, 2007 to May 2010. Mr. Bradway joined Amgen in 2006 and served as its Vice President of Operations Strategy. He served as Managing Director in investment banking at Morgan Stanley, where he was responsible for the Morgan Stanley's banking department and corporate finance activities in Europe. He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990, where he served as the Head of the Morgan Stanley's international health care investment banking activities. He has been the Chairman of Amgen Inc. since January 1, 2013. He has been an Independent Director of The Boeing Company since October 14, 2016. He has been a Director at Amgen Inc. since October 2011. He serves as a Trustee of University of Southern California. He served as an Independent Director of Norfolk Southern Corporation from July 2011 to May 11, 2017. He served as a Director of Micromet, Inc. from March 2, 2012 to March 7, 2012. He is chairman of the CEO Roundtable on Cancer, a non-profit organization comprised of executives founded to have solutions to cancer treatment and prevention. He holds a B.A in Biology from Amherst College and an MBA from Harvard University.

Howard Robin

CEO of Nektar Therapeutics

BIO: Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Therapeutics since January 15, 2007. From January 2001 to June 2001, he served as Chief Operating Officer and President of Prime Holdings & Investments Inc. He served as President and Chief Executive Officer of Sirna Therapeutics, Inc. since July 2001. Prior to Sirna Therapeutics, Inc., he served in a variety of functions during 20 years at Berlex Laboratories. From 1991 to 2001, Mr. Robin served as Corporate Vice President and General Manager of Berlex Laboratories Inc. From 1987 to 1991, he served as Vice President of Finance & Business Development and Chief Financial Officer of Berlex Laboratories Inc. From 1984 to 1987, he served as Director of Business Planning & Development at Berlex. Prior to Berlex, he served as a Senior Associate with Arthur Andersen & Company prior to joining Berlex. Mr. Robin has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. He serves as a Director of Acologix, Inc. He has been a Director of Nektar Therapeutics since February 14, 2007. Mr. Robin has been a Director of Sirna Therapeutics Inc. since July 2001. He served as a Director of Bay Area Bioscience Association. Previously, He served as a Director of Prime Holdings & Investments from January 2001 to June 2001. He received his B.S. in Accounting & Finance from Farleigh Dickinson University in 1974.